We previously reported cell cycle-dependent negative regulation of p185 neu (decreased tyrosine phosphorylation and kinase activity, with electrophoretic mobility retarded by serine/threonine phosphorylation) in M phase and the escape of mutation-activated p185 neu* from this regulation. Our present results showed that retardation of electrophoretic mobility occurs independently of the cells' transformed status. We found that normal p185
We previously reported cell cycle-dependent negative regulation of p185 neu (decreased tyrosine phosphorylation and kinase activity, with electrophoretic mobility retarded by serine/threonine phosphorylation) in M phase and the escape of mutation-activated p185 neu* from this regulation. Our present results showed that retardation of electrophoretic mobility occurs independently of the cells' transformed status. We found that normal p185
neu lost its ability to dimerize in the M phase. We demonstrated a physical association between cdc2 (a serine/threonine kinase, active in M phase) and p185
neu . We showed that the carboxy terminal portion of p185 neu is phosphorylated in vitro by cdc2. Many phosphopeptides (at least three phosphoserine residues) unique to the M phase were identi®ed, and the in vivo and in vitro phosphopeptide patterns were superimposable. In contrast, mutation-activated p185 neu* dimerized in the M phase with no changes in electrophoretic mobility, failed to associate with cdc2 and no unique phosphoserine residues could be identi®ed in the M phase (data not shown), consistent with the escape of p185 neu* from cell cycle-dependent regulation. Our results suggest that this escape is an intrinsic property of the mutation-activated p185 neu* independent of its ability to transform cells. Our results also suggest the involvement of serine/threonine kinases such as cdc2 in the cell cycle-dependent negative regulation of p185
Introduction
The HER2/neu/c-erbB-2 gene encodes a 185 kDa transmembrane glycoprotein (p185 neu ) that belongs to the EGF receptor family (Bargmann et al., 1986a,b; Bargmann and Weinberg, 1988a,b; Hung et al., 1986; Padhy et al., 1982; Schechter et al., 1984) . Members of this family are characterized by an extracellular, transmembrane, and the cytoplasmic tyrosine kinase domains. While the extracellular domain is involved in ligand binding, the cytoplasmic carboxy terminal tails display sequence heterogeneity and carry several tyrosine (including the autophosphorylation sites), serine, and threonine residues (Yarden and Ullrich, 1988) . In many cellular systems, both dimerization and tyrosine kinase activation follow second order kinetics with respect to receptor concentration, which implicates dimerization as an activating event for the kinase domain and suggests that the dimers are important structures in the propagation of mitogenic signals from the cell surface to the nucleus (Heldin, 1995) .
It is known that a single-point mutation in the transmembrane region (Val-644 to Glu) of neu converts the neu protooncogene into a transforming neu oncogene (neu*) (Bargmann et al., 1986a; Bargmann and Weinberg, 1988b; Hung et al., 1989; Muller et al., 1988; Stern et al., 1988) . The mutation-activated p185 neu* is associated with higher tyrosine kinase activity and exhibits more potent transforming ability than normal p185
neu (Bargmann and Weinberg, 1988a; Stern et al., 1988; Weiner et al., 1989) . Although a direct ligand of p185 neu is still not known, p185 neu* exists predominantly in the dimer form, and p185 neu exists as a monomer . Indeed, theoretical (Brandt-Rauf et al., 1990; Smith and Bormann, 1996; Sternberg and Gullick, 1990 ) and experimental evidence implied that the oncogenic mutation maintains the receptor in a dimer form that is analogous to the ligand-induced dimer of the EGF receptor (Yarden and Schlessinger, 1987a,b) . By dimerizing the receptor, the oncogenic mutation seems to establish a high anity binding state that is functionally equivalent to that of the ligand-occupied normal receptor (Ben-Levy et al., 1992) . We demonstrated that the structure and function of p185 neu are regulated through the cell cycle. In M phase, p185
neu is least active in tyrosine phosphorylation function and the regulation may occur through the alteration of phosphorylation of serine and/or threonine residues. Point mutation allowed p185 neu tyrosine kinase to escape cell cycle regulation as it remained constitutively active throughout the cell cycle (Kiyokawa et al., 1995) .
In the present study we sought further understanding of the mechanism of the cell cycledependent negative regulation of p185 neu we had shown. Using a cross-linking agent, we found that the normal p185 neu does not dimerize in the M phase, but that the oncogenic p185 neu* is dimerized. Further experiments with co-immunoprecipitation, in vitro kinase assays, and in vivo 32 P metabolic labeling methods, suggested the involvement of cdc2, an M phase-speci®c serine/threonine kinase, in the negative regulation.
Results
Escape from cell cycle-dependent regulation is an intrinsic property of the mutation-activated p185 neu* , independent of its ability to transform cells As shown earlier, the normal p185 neu protein is regulated in a cell cycle-dependent manner, whereas the p185 neu* (with a point mutation in the transmembrane region) escapes from this regulation. With cellcycle progression, tyrosine phosphorylation and tyrosine kinase activity of p185 neu gradually decreased, reaching their minimum level in M phase. An overall hyperphosphorylation in the serine and/or threonine residues resulted in an electrophoretic mobility shift in the M phase. The oncogenic p185 neu* protein tyrosine kinase was constitutively active in both G 0 /G 1 and M phases while the protein's electrophoretic mobility did not change signi®cantly. Thus, the single-point mutation in the transmembrane domain facilitated the escape of p185 neu* from cell cycle dependent negative regulation of p185 neu tyrosine kinase activity, possibly as a result of serine/threonine phosphorylation (Kiyokawa et al., 1995) . Since the single-point mutation also induced cellular transformation, it was pertinent to ask whether the absence of the mobility shift in M phase is a speci®c property of the mutated neu* or is caused by the transformation per se. To address this question, NIH3T3 cells (expressing endogenous p185 neu ) transformed by dierent oncogenes (ras, src and abl) were synchronized either in G 0 / G 1 or M phase and their electrophoretic mobility was analysed after their cell cycle stage was con®rmed by DNA content analysis. As shown in the two upper panels of Figure 1 , DNA content analysis con®rmed that the serum starvation synchronized the parental NIH3T3 and the transfected cells in G 0 /G 1 stage, and that nocodazole treatment arrested these cells in the M phase. The results, shown in the lower panel of Figure  1 depicting the electrophorectic mobility changes in p185 neu detected by Western blotting, indicate retarded migration of the protein in M phase in all cells analysed. Mutated p185 neu* did not show a change in electrophoretic mobility at dierent stages of the cell cycle (Kiyokawa et al., 1995) and the cells transformed by various oncogenes (ras, src and abl) also showed retarded electrophoretic mobility (Figure 1 ). These results suggested that the escape from cell cycledependent regulation is an intrinsic property of the mutation-activated p185 neu* , independent of its ability to transform cells.
Normal p185
neu fails to dimerize in M phase but not the mutation-activated p185 neu* Since the function of p185 neu is tightly associated with its dimerization status , we next asked whether this could account for the negative regulation of p185 neu in M phase and the escape of p185 neu* from this process. We used derivatives of NIH3T3 cells that express the normal neu (DHFR/G8) and the mutated neu* (B104-1-1). After synchronizing these cells in G 0 /G 1 or M phase, they were crosslinked and p185 neu proteins were analysed by Western blotting. As predicted, the DHFR/G8 cells failed to dimerize in the M phase, and the dimerization status remained unaltered in B104-1-1 cells between G 0 /G 1 and M phases (Figure 2 ). Immunoprecipitation of p185 neu after crosslinking under the same conditions also gave similar results (data now shown).
Added to our previous report (Kiyokawa et al., 1995) , these data suggested that, in M phase of the cell cycle, the serine/threonine hyperphosphorylation of p185 neu may prevent receptor dimerization, which in turn inhibits the tyrosine kinase activity of p185 neu and intrinsically aids the escape of p185 neu* from this regulation.
Physical association between cdc2 and p185 neu Interestingly, cdc2, a serine/threonine kinase, is most active in M phase (Bischo et al., 1990; Draetta and Beach, 1988; Lee and Nurse, 1987; Shenoy et al., 1989) . Perhaps not by coincidence, a careful examination of the amino acid sequence of p185 neu revealed no less than 17 potential sites for cdc2. To see whether the two dierent kinases, cdc2 and p185 neu , are physically associated, we immunoprecipitated the cell lysates of DHFR/G8 expressing normal p185 neu and B104-1-1 expressing p185 neu* with a monoclonal antibody to cdc2 or with normal mouse serum (NMS) and immunoblotted them with a monoclonal antibody to p185 neu or cdc2. The results shown in Figure 3a indicated that these two proteins are physically associated in DHFR/ G8 cells, but not in B104-1-1 cells that express p185 neu* . These results were ascertained by using three dierent antibodies to immunoprecipitate cdc2 under the same experimental conditions (data not shown). We also examined the physical association between cdc2 and p185 neu in dierent stages of the cell cycle in DHFR/G8 cells, by chemical synchronization, and found relatively abundant association between them at G2/M phase ( Figure 3b ). cdc2 can phosphorylate p185 neu in vitro
Encouraged by the physical association of cdc2 and p185 neu in DHFR/G8 cells, we used an in vitro complex kinase assay to investigate whether cdc2 can phosphorylate p185 neu . Phosphorylation of p185 neu by cdc2 was observed when the p185 neu was immunoprecipitated from the DHFR/G8 cells and then mixed with commercially available active cdc2, or when the cell lysates from DHFR/G8 cells were frozen and thawed a few times after immunoprecipitation (to reduce the autophosphorylation activity of p185 neu tyrosine kinase) and mixed ( Figure 3c ). Phosphorylation of p185 neu was not seen, however, when cdc2 or p185 neu was present alone in the reaction mixture ( Figure 3c ). The phosphorylated band of p185 neu from the above experiment was further examined by phosphoamino acid analysis, and the results con®rmed the involvement of phosphorylation of serine and threonine but not of tyrosine residues ( Figure 3d ) which was predictable from the known action of cdc2 as a serine/threonine kinase. Using dierent antibodies to immunoprecipitate cdc2, we also con®rmed that the immunoprecipitated p185 neu from DHFR/G8 cells could be phosphorylated by cdc2 in vitro (data not shown).
cdc2 phosphorylates the carboxy terminal of p185 neu In an attempt to locate the phosphorylation sites of p185 neu in M phase by cdc2, we carried out an in vitro and in vivo two-dimensional phosphopeptide mapping analysis. The approximate positions of the potential phosphorylation sites for cdc2 in the p185 neu protein are schematically shown in Figure 4a . The drawing depicts GST-fusion protein that represents the carboxy terminal region of p185 neu (YX1) and contains most of the serine and threonine residues, and another GST protein (YX3) that contains a few serine and threonine residues constructed from the kinase domain and the juxtamembrane portion of p185 neu . The expression of these fusion proteins was revealed by coomassie blue staining of the bacterial cell lysates and the major proteins of expected size were stained heavily by the dye and further con®rmed by immunoblotting analysis, which showed that an antibody directed against the carboxy terminal tail of neu detected only YX1 and not YX3 (Figure 4b) . Similarly, the use of an antibody against the kinase domain reacted with YX3 but not YX1, as expected ( Figure 4b ). These fusion proteins were then used in an in vitro complex kinase assay that utilized the commercially available puri®ed cdc2 (UBI). The results showed that only YX1 made from the carboxy terminal of p185 neu was phosphorylated when mixed with cdc2, and that cdc2 : YX3 mix had no such eect (Figure 4c ). Phosphorylation was not observed when either YX1 or YX3 was present in the reaction mixture without cdc2 (data not shown). Taken together, these results strongly suggested the existence of potential phosphorylation sites for cdc2 at the carboxy terminal tail of p185 neu .
In vitro and in vivo phosphopeptide patterns are superimposable
The possible relevance of cdc2-mediated phosphorylation of p185 neu observed in vitro was next examined in vivo by metabolic labeling of DHFR/G8 cells with 32 P before (unsynchronized) or after the cells were synchronized in G 0 /G 1 or M phase and their phosphopeptide pattern analysed, as shown in Figure  5 . When phosphopeptides from G 0 /G 1 and M phase were mixed together and analysed, more than nine phosphopeptides unique to the M phase could be identi®ed, along with two phosphopeptides unique to the G 0 /G 1 phase, and several phosphopeptides common to both G 0 /G 1 and M phases. Phosphoamino acid analysis of the phosphopeptides revealed that at least three phosphopeptides unique to the M phase contained phosphorylated serine residues, and several such residues were found also in the phosphopeptides common to both phases of the cell cycle ( Figure 5 ). When a similar experiment was done with B104-1-1 cells, the phosphopeptide patterns of G 0 /G 1 and M phases were virtually identical (notably, they resembled the G 0 /G 1 stage of DHFR/G8 cells), and no unique phosphoserine residues could be identi®ed in the M phase (data not shown), consistent with the escape of p185 neu* from cell cycle-dependent regulation. Thus, our results suggested that cdc2 can phosphorylate p185 neu in M phase in DHFR/G8 cells. If this is indeed the case, the in vitro and in vivo phosphopeptide mapping patterns should be similar. When the phosphopeptides obtained from the YX1-cdc2 complex ( Figure 4c) were mixed with the in vivo -labeled phosphopeptides prepared from the M phase synchronized DHFR/G8 cells and analysed, we found more than 10 common phosphopeptide spots among the in vivo and in vitro patterns ( Figure 6 ). Phosphoamino acid analysis helped us to identify at least ®ve phosphoserine-containing phosphopeptides among them, supporting the involvement of cdc2. The presence of several such peptides unique to the M phase ( Figure 6 ) indicated that other serine/threonine kinases could also be involved in the negative regulation of p185 neu .
Discussion
We pursued our earlier report which showed the disruption of the cell-cycle dependent regulation of normal p185 neu by its oncogenic counterpart p185 neu*
and de®ned a plausible mechanism of cellular neu with cdc2. The proteins were immunoprecipitated with a monoclonal anti-cdc2 antibody (a cdc2) or normal mouse serum (NMS) from 500 mg of precleared lysate of DHFR/G8 or B104-1-1 cells. After intensive washing with lysis buer, samples were separated on 6 ± 10% SDS ± PAGE gradient gel and transferred onto a nitrocellulose membrane. The membrane was cut into two parts to detect both p185 neu and cdc2 by immunoblotting with either monoclonal anti-p185 neu antibody (c-neu (Ab3), upper panel) or monoclonal anti-cdc2 antibody (acdc2, lower panel). (b) Cell cycle dependent association of p185 neu with cdc2. DHFR/G8 cells were synchronized at dierent stages of cell cycle as described in Materials and methods. Cell lysates were prepared, immunoprecipitated and analysed as described for a. (c) In vitro phosphorylation of p185 neu by cdc2. The ability to phosphorylate p185 neu was tested by an in vitro immune complex kinase assay. Immunoprecipitated p185 neu proteins from DHFR/G8 were equally divided into two parts and mixed with (+) or without (7) the puri®ed cdc2 protein (25 ng/assay) followed by incubation with [g-32 P]ATP and MgCl 2 for 20 min at room temperature. After separation on 7% SDS ± PAGE gel samples were exposed on X-ray ®lm. To minimize autophosphorylation activity, proteins denatured by repeated freezing and thawing were tested in a similar manner. (Kiyokawa et al., 1995) . The present results clari®ed that the disruption is not caused by the transformation per se (Figure 1 ), but that the escape of p185 neu* from regulation may be an intrinsic property of the mutated protein. We had predicted that the negative regulation of normal p185 neu tyrosine kinase activity observed in M phase of the cell cycle in DHFR/G8 cells and an escape from this regulation in B104-1-1 cells that express p185 neu* (Kiyokawa et al., 1995) could be the result of a disequilibrium between the p185 neu receptor's monomeric and dimeric forms. The results shown in Figure 2 lend strong support to this prediction because the dimers could not be captured by crosslinking during M phase in DHFR/ G8 cells. Weiner et al. (1989) have analysed the formation of dimers in detail in DHFR/G8 and B104-1-1 cells. They found that about 70% of the oncogenic p185 neu* exists as an aggregated crosslinkable complex, and 20 ± 30% of normal p185 neu in DHFR/G8 cells can be cross-linked under identical conditions. It is interesting to note that, in a family of bacterial receptors that have the same topology as the eukaryotic single-transmembrane receptors, general structural changes (such as a monomer-to-dimer transition) seem to have been responsible for transmembrane signaling rather than speci®c ligand-induced conformational changes (Stock, 1996) . Ligand-independent dimerization is known to occur in oncogenic tyrosine and serine/threonine receptor kinases (Adelsman et al., 1996; Carlberg and Rohrschneider, 1994; Vivien et al., 1995; Watowich et al., 1992; .
More intriguing is the mechanism by which such negative regulation results in the failure to dimerize (Figure 2 ) and the consequent decrease in tyrosine kinase activity and signaling of the normal p185 neu receptor (Kiyokawa et al., 1995) in M phase. We hypothesized that it is due to the hyperphosphorylation of serine/threonine residues in M phase and the amino acid mutation in p185 neu* disrupts this regulation. The presence of more phosphopeptide spots (at least 3 containing phosphoserine residues) in the M phase than in the G 0 /G 1 phase (which had no phosphoserine residues) of DHFR/G8 cells that express normal p185 quali®es it as a potential candidate for the described negative regulation. Consistent with these structural features and M phase-speci®c activity are our experimental results (Figure 3a and b) which show that physical association between these two proteins is stronger at G2/M phase of the cell cycle. Though cdc2 is a nuclear protein, its existence and activation in the cytoplasm has also been reported (Heald et al., 1993) . Our results demonstrated cdc2 site of action to be the carboxy terminal of p185 neu (Figure 4) after showing cdc2 to be capable of phosphorylating p185 neu in vitro and the phosphorylation sites to overlap with those in vivo (Figures 3 and 5) . Furthermore, the superimposable phosphopeptide patterns obtained when in vitro cdc2-phosphorylated YX1 (carboxy-terminal p185 neu -GST fusion protein) was mixed with the in vivo labeled M phase-synchronized DHFR/G8 cells (Figure 6 ) strongly suggested the involvement of cdc2. Further work is needed to locate speci®c serine/ threonine residues in p185 neu phosphorylated by cdc2. Mutation of such residues would reveal their relative functional importance, though the question is complicated by the presence of several serine/threonine residues. Puri®ed Xenopus laevis p34cdc2 was reported to phosphorylate the EGFR on serine 1002 in vitro, implying that receptor function may be regulated in a cell cycle-dependent fashion (Kuppuswamy et al., 1993) . In addition, the in vitro phosphorylation was associated with an inhibition of EGFR tyrosine kinase activity. A comparison of the sequences of several growth factor receptors showed that the string of acidic residues, followed by the Ser-Pro motif found at residues 1002 ± 1003 of the EGFR, a proposed cdc2 phosphorylation site, is conserved in most EGFR family members, including p185 neu (Bargmann et al., 1986a) , ErbB-3 (Plowman et al., 1990) , and let-23, the EGFR homologue in C. elegans (Aroian et al., 1990) . However, a role for these cell cycle stage-speci®c phosphorylations remains an intriguing possibility in the negative regulation of the receptor tyrosine kinases, including the EGFR and p185 neu . A better known physiological feedback-inhibitory mechanism involves protein kinase C (PKC), a serine/threonine kinase, which phosphorylates threonine 654 residue on the EGFR, decreasing the receptor's binding anity for ligands (Morrison et al., 1993) , diminishing tyrosine kinase activity (Cochet et al., 1984; Davis, 1988) , and attenuating signals from the EGFR (Chen et al., 1996) . 
Feedback inhibition of p185
neu tyrosine kinase activity by PKC-mediated serine/threonine phosphorylation has also been reported (Cao et al., 1991; Dobashi et al., 1989) . Although our results suggested the involvement of cdc2 in the phosphorylation of p185 neu , they do not rule out the involvement of other kinases in the process. The presence of additional phosphopeptides, several of them containing phosphoserine residues, in in vivo -labeled DHFR/G8 cells in M phase (Figure 6 ) already indicates this possibility. HER2/neu is phosphorylated in vitro on a single site in the cytoplasmic tail at threonine 1172 by the calmodulin-dependent protein kinase II (Feinmesser et al., 1996) . The consensus sites of cdc2 (basic-Ser/ Thr-Pro-polar-basic or basic/polar-Ser/Thr-Pro-Xbasic) are, in fact, quite similar to those of MAP kinase (Pro-X-Ser/Thr-Pro), another Ser/Thr kinase, where X represents any amino acid present in proteins (Langan et al., 1989; Lin et al., 1991; Shenoy et al., 1989) . In addition, the platelet-derived growth factor receptor (Yarden et al., 1986) and ®broblast growth factor receptor (Lee et al., 1989 ) also contain Ser-Pro motifs in the region C terminal to the kinase domain, although they lack the acidic region upstream from this sequence. Serine/threonine phosphorylation is likely to be a general phenomenon since a number of growth factor receptors could be phosphorylated by a prolinedirected kinase in this region. It would be interesting to analyse the action of various serine/threonine kinases and their involvement in and relative contribution to negative regulation of receptor tyrosine kinases in general and the cell cycle in particular.
Materials and methods

Cell culture and synchronization
Cell lines that express the normal p185 neu (DHFR/G8) and the mutation-activated p185 neu* have been described (Hung et al., 1986; Kiyokawa et al., 1995; Padhy et al., 1982) . NIH3T3 cells were transfected with ras, src and abl oncogenes (NIH/ras, NIH/src, NIH/abl) as described earlier (Matin and Hung, 1994) . Cells were grown in Dulbecco's modi®ed Eagle medium : nutrient mixture F-12 (DMEM/F12 1 : 1) (GIBCO) supplemented with 10% fetal calf serum at 378C in a humidi®ed 5% CO 2 atmosphere. Cells at half-con¯uence were starved in DMEM/F12 with 0.5% FCS for 48 h to arrest them in G 0 /G 1 phase (Welch and Wang, 1993) . To accumulate in pre-S phase and G2 phase, cells were incubated with aphidicolin and Hoechst 33342, respectively, as described (Kiyokawa et al., 1995) . To synchronize the cells in M phase, they were incubated with DMEM/F12 containing 10% fetal calf serum and nocodazole (0.4 mg/ml) for 12 ± 24 h, afterwhich cells that had a highly rounded mitotic shape were collected by mechanical shake-o. More than 90% of the nocodazoletreated shaken o cells were tetraploid according to DNA content analysis (Chackalaparampil and Shalloway, 1988) . The adherent cells after nocodazole treatment were considered to be in G2/M phase.
DNA content analysis
For DNA content analysis, trypsinized cells were ®xed for 30 min at 7208C in 70% ethanol-30% PBS mixture. After staining with PBS containing 5 mg/ml propidium iodide and 8 mg/ml RNAse A, cells were analysed on an EPICS PROFILE¯ow cytometer (Coulter) as described previously (Chackalaparampil and Shalloway, 1988) . The results were analysed with the MultiCycle computer program (Pheonix Flow System).
Antibodies
Anti-cdc2 monoclonal antibody p34 (Santa Cruz Biotechnology Inc.,) was used for both immunoprecipitation and immunoblotting. Anti-p185 neu monoclonal antibody raised against the c-terminal (Ab-3) or the extracellular portion (Ab-4) and a rabbit antibody raised against the kinase domain (Ab-1) were obtained from Oncogene Science.
Generation of GST-p185
neu fusion proteins cDNA fragments that correspond to dierent parts of the intracellular portion of rat p185 neu were ampli®ed by PCR from pSV2neu and subcloned into pGEX-3X bacterial M specific cdc2 specific common for G0/G1 & M but not cdc2 Figure 6 Comparison of the patterns of phosphopeptides and phosphoamino acids obtained from the in vitro and in vivo phosphorylation of p185 neu protein. DHFR/G8 cells were metabolically labeled after treatment with nocodazole and analysed as described in Figure 5 and the phosphopeptide spots are shown in panel 1. The recombinant-GS-p185 neu fusion protein (YX-1) was phosphorylated and analysed as described in Figure 4 and shown in panel 2. The phosphopeptide pattern obtained after mixing the samples from panels l and 2 are shown in panel 3. Phosphoamino acid analysis of individual spots from panel 3 revealed the prescence of several phosphoserine-containing peptides (S) as shown in the schema (panel 4). These results were con®rmed in another independent experiment cdc2 phosphorylates p185 neu N Kiyokawa et al expression vector (Pharmacia) at HindIII and SmaI sites. The GST-fusion proteins, YX-1 representing amino acids 934 ± 1260 and YX-3 representing amino acids 681 ± 993 of p185 neu , were produced in bacteria and puri®ed.
Immunoprecipitation and Western blotting
After each treatment, cells were solubilized for 30 min on ice in lysis buer (20 mM Na 2 PO 4 , pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin, 100 mM NaF and 2 mM Na 3 VO 4 ) and the total protein concentration was determined using the Bio-Rad protein assay kit. Electrophoretically separated proteins were transferred to a nitrocellulose membrane for 1 h at 3 mA/cm 2 using a semidry transblot system (Bio-Rad). After being blocked with PBS containing 5% milk, membranes were incubated with primary antibodies for 1 h at room temperature in 3% BSA/PBS, then washed with 0.05% Tween 20 in PBS. After 30 min of incubation with an appropriate secondary antibody conjugated with horseradish peroxidase and a subsequent washing with PBS-0.05% Tween 20, immunoblots were developed by the enhanced chemiluminescence reagent (ECL, Amersham) for 1 min and exposed to ®lm (Hyper-®lm, Amersham). For immunoprecipitations, 500 mg to 1 mg of cell lysates were incubated with 1 mg of antibody and 50 ml of 50% protein-A agarose for 1 h at 48C. After several washes with 0.05% Tween 20/PBS, immunoprecipitates were separated by electrophoresis and analysed.
Chemical crosslinking
Cells synchronized in the G 0 /G 1 or M phase were washed with PBS twice and incubated with 1 mM bis(sulfosuccinimidyl) suberate (BS 3 ) in PBS for 30 min at 48C, with rocking. The cells were solubilized with PI/RIPA buer .
In Vitro immune complex kinase assay
Commercially available cdc2 complex (Upstate Biotechnology Incorporated, New York) puri®ed from the sea star Pisaster ochraceus was mixed with either the immunoprecipitated p185 neu proteins or the recombinant GST-p185 neu proteins. After being washed four times, once with PBS, twice with 50 mM Tris-HCl (pH 7.5) containing 0.5 M LiCl and once with kinase assay buer (50 mM Tris, 10 mM MgCl 2 , pH 7.5), the immunoprecipitates were incubated for 20 min at room temperature in 50 ml of kinase buer, with 10 mCi of [ 32 P]g-ATP (speci®c activity 43000 Ci/mM; Amersham). Reactions were stopped by adding 10 ml of 66SDS-sample loading buer. After separation on a 7% SDS ± PAGE gel, phosphorylated proteins were visualized with autoradiography.
P metabolic labeling
Cells were metabolically labeled with 32 P-orthophosphate (500 mCi/ml, carrier-free; Amersham) for 8 h in phosphatefree DMEM supplemented with either 0.5% or 10% dialyzed FCS (Epstein et al., 1990) .
Phosphopeptide and phosphoamino acid analysis
In vitro or in vivo 32 P-labeled p185 neu proteins were excised and extracted from SDS ± PAGE gel as described previously (Cooper et al., 1983) . One portion was digested with TPCK-treated trypsin and the peptides were separated on TLC plates by electrophoresis (horizontal direction, anode on left) in pH 3.5 buer and chromatography (vertical direction) as described previously (Kiyokawa et al., 1995) . Another portion was hydrolyzed in 6 N constantly boiling HCL for 60 min at 1108C and separated on TLC plates with unlabeled phosphoamino acid standards by two-dimensional electrophoresis for phosphoamino acid analysis. In both cases, phosphopeptides and phosphoamino acids were detected by autoradiography and the positions of phosphoamino acids were visualized by ninhydrin staining.
